Abstract Library

#4611 Management strategies and outcomes for type 1 gastric neuroendocrine tumours measuring > 1cm in diameter

Introduction: Although type 1 gastric neuroendocrine tumours (T1-gNETs) are usually considered indolent diseases, the management and the outcome of tumours >1cm remain not well established.

Conference:

Presenting Author:

Authors: Dell' Unto E, Srirajaskanthan R, Saini A, Salin G, de Mestier L,

Keywords: gastric neuroendocrine tumour, gastric carcinoid, endoscopic treatment,

#4571 Characterisation and prognostic impact of carcinoid syndrome in bronchial neuroendocrine tumours

Introduction: Metastatic bronchial neuroendocrine tumours (MBNET) are associated with carcinoid syndrome in 10 to 40% of cases. Characteristics of carcinoid heart disease (CHD) are poorly described.

Conference:

Presenting Author: Baudin E

Authors: Hescot S, Marret G, Hadoux J, Laboureau S, Haissaguerre M,

Keywords: bronchial NET, carcinoid syndrome, 5HIAA, carcinoid heart disease,

#4196 Metastatic potential and associated mortality in a Greek cοhort of 123 MEN1 patients

Introduction: Prevalence of distant stage disease and overall mortality rates vary considerably among patients with multiple endocrine neoplasia type 1 (MEN1).

Conference:

Presenting Author: Papadopoulou-Marketou N

Authors: Papadopoulou-Marketou N, Daskalakis K, Chondrogianni M, Tsoli M, Kaltsas G,

Keywords: MEN1, pancreatic neuroendocrine tumor, thymus cancer,

#3786 Overview of screening and surveillance practices for MEN1-related pancreatic neuroendocrine neoplasms in ENETS CoEs – An ENETS MEN1 Task Force Questionnaire Study

Introduction: The 2012 MEN1 Clinical Practice Guidelines were based on expert opinion with limited evidence, leaving room for interpretation and variation in practices.

Conference:

Presenting Author:

Authors: Pieterman C, Kaltsas G, Valk G, On Behalf of the Enets Men1 Task Force N,

Keywords: men1, screening, surveillance, PanNEN, ENETS CoE, Questionnaire,

#3500 HomeLAN: An international online survey to assess satisfaction with injection experience of patients with neuroendocrine tumors (NETs) enrolled in lanreotide autogel (LAN) Patient Support Programmes (PSPs)

Introduction: LAN is a long-term treatment for NETs, delivered in a ready-to-use syringe by monthly, deep subcutaneous injection. LAN PSPs aim to assist patients receiving their treatment at home, reducing both travel burden and the current risk of COVID-19 exposure. Furthermore, after training patients on stable dose can administer LAN independently (self or non-healthcare professional), where approved.

Conference:

Presenting Author: Hernando J

Authors: Hernando J, Kolarova T, Verslype C, Kaltsas G, Houchard A,

Keywords: neuroendocrine tumor, patient satisfaction, patient support programme, patient survey, lanreotide autogel,